Sign In
to Vote &
Create Storyboards.
 

Brentuximab vedotin shows extended survival in HL and sALCL

Medical News Today - 12 Dec 2013 13:00
Updated 3-year results for two brentuximab vedotin (Adcetris™) pivotal phase II trials in patients with relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma both showed extended survival for these heavily pre-treated patients. The studies were presented at the 55th American Society of Hematology meeting, held in New Orleans, LA, December 7-10, 2013.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard